A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

Launched by GATES MEDICAL RESEARCH INSTITUTE · Nov 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called TBD11 to see how safe it is and how it behaves in the body when given to healthy adults. The trial is split into two parts: the first part will test single doses of the medication along with how food affects its absorption, while the second part will look at multiple doses over time. The main goal is to gather information on how the medication works in people who do not have any health issues.

To participate in this trial, you need to be a healthy adult aged 18 to 65, with a body mass index (BMI) between 18 and 32, and weigh at least 50 kg. You'll also need to be able to understand the trial's procedures and provide written consent. Participants will spend some time at the research facility during the study, where they'll be monitored closely. It's important to know that certain medical conditions and a history of serious health issues may disqualify someone from joining. If you're interested in learning more or think you might qualify, please reach out for more information!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Is healthy as determined by the Investigator via medical history and clinical examination before enrolment in the trial.
• • Can understand and comply with the trial and site procedures, understand the risks involved in the trial, and provide written informed consent before the first trial-specific procedure.
• • Can complete all Screening period evaluations and stay in the clinical research facility for the duration of the inpatient periods of the trial.
• • Has BMI between 18 and 32 kilograms per meter square (kg/m2), inclusive, and body weight not less than 50 kg at Screening.
• * Has resting vital signs within the following ranges:
• • 1. Systolic blood pressure (SBP) \>= 100 millimeters of Mercury (mmHg) and \<= 140 mmHg
• • 2. Diastolic blood pressure (DBP) \>= 60 mmHg and \<= 90 mmHg
• • 3. Heart rate between 50 and 100 beats per minute (bpm)
• * If individual's assigned sex at birth is female, they must have negative urine and serum pregnancy tests at Screening, and be of non-childbearing potential based on either of the following:
• • 1. Is post-menopausal defined as amenorrhea for at least 12 months in absence of any exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the laboratory-defined postmenopausal range, or,
• • 2. Reports being surgically sterilized (ie, tubal ligation, hysterectomy, bilateral oophorectomy/salpingectomy), and provides written documentation \[(ie, medical record(s)\], where feasible, to document such procedure(s) to the Principal Investigator. The site must make documented attempts to obtain medical records. If records cannot be retrieved, a participant may be enrolled at the Principal Investigator's discretion.
• Exclusion Criteria:
• • Has current or past history of a clinically significant cardiovascular, cerebrovascular, respiratory, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease, as determined by the Investigator.
• • Has history of or has clinically relevant cardiovascular disorder, such as heart failure, coronary artery disease, controlled or uncontrolled hypertension, arrhythmia, tachyarrhythmia, prolonged QT syndrome, or presence of symptom(s) strongly suggestive of such a problem, such as exertional chest pressure/pain or unexplained syncope.
• • Had an active malignancy within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or melanoma will be exclusionary.
• • Has history of any drug abuse within 1 year prior to Screening or has used any hard drugs (such as cocaine, phencyclidine \[PCP\], natural and synthetic opiates, and amphetamine derivatives) within 1 year prior to Screening. Individuals that have taken an opioid or amphetamine medication within the previous year prior to Screening that was prescribed by a healthcare provider will not be excluded unless they are currently taking the medication at the time of Screening.
• • Had any surgical or medical condition or history that, in the opinion of the Investigator, may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to, gastric bypass, sleeve, banding surgery, or gastric or duodenal ulcers.
• • Additional inclusion/exclusion criteria are defined in the protocol.